New agents and new formulations for the treatment of ovarian cancer.
Sabbatini
Paul
P
Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, USA.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D018394:CA-125 Antigen / Q000097:blood; D004149:Dioxoles / Q000627:therapeutic use; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011237:Predictive Value of Tests; D011799:Quinazolines / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D015996:Survival Rate; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018394:CA-125 Antigen; D004149:Dioxoles; D007546:Isoquinolines; D011799:Quinazolines; D044005:Tetrahydroisoquinolines; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; C107428:oregovomab; D000077606:Trabectedin